Advertisement
Canada markets open in 3 hours 56 minutes
  • S&P/TSX

    22,107.08
    +194.56 (+0.89%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • DOW

    39,760.08
    +477.75 (+1.22%)
     
  • CAD/USD

    0.7348
    -0.0025 (-0.33%)
     
  • CRUDE OIL

    81.66
    +0.31 (+0.38%)
     
  • Bitcoin CAD

    96,171.23
    +1,213.39 (+1.28%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,216.40
    +3.70 (+0.17%)
     
  • RUSSELL 2000

    2,114.35
    +44.19 (+2.13%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • NASDAQ futures

    18,467.75
    -36.00 (-0.19%)
     
  • VOLATILITY

    12.99
    +0.21 (+1.64%)
     
  • FTSE

    7,963.51
    +31.53 (+0.40%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6814
    +0.0009 (+0.13%)
     

Eric Sprott Announces Holdings in Entheon Biomedical Corp., (Formerly, MPV Exploration Inc.)

Toronto, Ontario--(Newsfile Corp. - December 3, 2021) - Eric Sprott announces that, today, 600,000 common share purchase warrants (Warrants) of Entheon Biomedical Corp., (held by 2176423 Ontario Ltd., a corporation he beneficially owns) expired unexercised representing a decrease in holdings of approximately 4.2% of the outstanding common shares (Shares) on a partially diluted basis since the date of the last early warning report. Prior to the expiry of these Warrants, Mr. Sprott beneficially owned and controlled 3,200,000 Shares and 1,100,000 Warrants representing approximately 5.4% of the outstanding Shares on a non-diluted basis and approximately 7.2% on a partially diluted basis assuming the exercise of such Warrants.

As a result of the Warrant expiry, Mr. Sprott now beneficially owns and controls 3,200,000 Shares and 500,000 Warrants representing approximately 5.4% of the outstanding Shares on a non-diluted basis and approximately 6.2% on a partially diluted basis. The Warrants expiry resulted in partially diluted ownership to decrease below 10% and, therefore, Mr. Sprott is no longer a "reporting insider."

The securities are held for investment purposes. Mr. Sprott has a long-term view of the investment and may acquire additional securities including on the open market or through private acquisitions or sell the securities including on the open market or through private dispositions in the future depending on market conditions, reformulation of plans and/or other relevant factors.

ADVERTISEMENT

Entheon Biomedical is located at Suite 720-999 W Broadway Street, Vancouver, British Columbia, V5Z 1K5. A copy of the early warning report with respect to the foregoing will appear on the company's profile on the System for Electronic Document Analysis and Retrieval at www.sedar.com and may also be obtained by calling Mr. Sprott's office at (416) 945-3294 (2176423 Ontario Ltd., 200 Bay Street, Suite 2600, Royal Bank Plaza, South Tower, Toronto, Ontario M5J 2J1).

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/106545